While the small molecule inhibitor targeting BCL-2/BCL-xL/BCL-w (ABT-263) as a single agent has entered clinical experimentation in certain cancers, NSCLC is largely resistant to these inhibitors alone (Fig. S2A). This evidence concerns the gene BCL2 and non-small cell lung carcinoma.